La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Firebrick Pharma Performance dei guadagni passati
Il passato criteri di controllo 0/6
Firebrick Pharma's earnings have been declining at an average annual rate of -33.8%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 64.7% per year.
Informazioni chiave
-33.8%
Tasso di crescita degli utili
1.7%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 31.2% |
| Tasso di crescita dei ricavi | 64.7% |
| Rendimento del capitale proprio | -287.5% |
| Margine netto | -251.6% |
| Ultimo aggiornamento sui guadagni | 31 Dec 2023 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14
We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30Ripartizione dei ricavi e delle spese
Come Firebrick Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -5 | 2 | 4 |
| 30 Sep 23 | 1 | -6 | 2 | 4 |
| 30 Jun 23 | 0 | -7 | 2 | 4 |
| 31 Mar 23 | 1 | -6 | 2 | 4 |
| 31 Dec 22 | 1 | -5 | 2 | 4 |
| 30 Sep 22 | 1 | -5 | 2 | 3 |
| 30 Jun 22 | 1 | -4 | 2 | 2 |
| 31 Mar 22 | 1 | -3 | 2 | 2 |
| 31 Dec 21 | 0 | -3 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 2 | 1 |
| 30 Jun 20 | 1 | -1 | 0 | 2 |
Guadagni di qualità: FRE is currently unprofitable.
Margine di profitto in crescita: FRE is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: FRE is unprofitable, and losses have increased over the past 5 years at a rate of 33.8% per year.
Accelerare la crescita: Unable to compare FRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: FRE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendimento del capitale proprio
ROE elevato: FRE has a negative Return on Equity (-287.46%), as it is currently unprofitable.